Marcus Renner

Marcus Renner

Auto-generated profile, based on publicly available information

Marcus Renner

Department of General Pathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2017 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
PCPriya Chudasama
Priya Chudasama
MRMarcus Renner
Marcus Renner
MSMelanie Straub
Melanie Straub
SMSadaf S. Mughal
Sadaf S. Mughal
BHBarbara Hutter
Barbara Hutter
SFStefan Fröhling
Stefan Fröhling
Purpose: Altered FGFR1 signaling has emerged as a therapeutic target in epithelial malignancies. In contrast, the role of FGFR1 in soft-tissue sarcoma (STS) has not been established. Prompted by the detection and subsequent therapeutic inhibition of amplified FGFR1 in a patient with metastatic leiomyosarcoma, we investigated the oncogenic properties of FGFR1 and its potential as a drug target in patients with STS. Experimental Design: The frequency of FGFR1 amplification and overexpression, as assessed by FISH, microarray-based comparative genomic hybridization and mRNA expression profiling, SNP array profiling, and RNA sequencing, was determined in three patient cohorts. The sensitivity of STS cell lines with or without FGFR1 alterations to genetic and pharmacologic FGFR1 inhibition and the signaling pathways engaged by FGFR1 were investigated using viability assays, colony formation assays, and biochemical analysis. Results: Increased FGFR1 copy number was detected in 74 of 190 (38.9%; cohort 1), 13 of 79 (16.5%; cohort 2), and 80 of 254 (31.5%; cohort 3) patients. FGFR1 overexpression occurred in 16 of 79 (20.2%, cohort 2) and 39 of 254 (15.4%; cohort 3) patients. Targeting of FGFR1 by RNA interference and small-molecule inhibitors (PD173074, AZD4547, BGJ398) revealed that the requirement for FGFR1 signaling in STS cells is dictated by FGFR1 expression levels, and identified the MAPK–ERK1/2 axis as critical FGFR1 effector pathway. Conclusions: These data identify FGFR1 as a driver gene in multiple STS subtypes and support FGFR1 inhibition, guided by patient selection according to the FGFR1 expression and monitoring of MAPK–ERK1/2 signaling, as a therapeutic option in this challenging group of diseases. Clin Cancer Res; 23(4); 962–73. ©2016 AACR.

28 January 2017 in Histopathology
Verified
Journal Article
Closed access
PDF file
BGBenjamin Goeppert
Benjamin Goeppert
SRStephanie Roessler
Stephanie Roessler
NBNatalia Becker
Natalia Becker
MZManuela Zucknick
Manuela Zucknick
MVMonika N Vogel
Monika N Vogel
MRMarcus Renner
Marcus Renner

18 May 2006 in Zeitschrift für Geburtshilfe und Neonatologie
Verified
Journal Article
Closed access
HMH. Müller
H. Müller
CEC. End
C. End
MRM. Renner
M. Renner
BHB. M. Helmke
B. M. Helmke
NGN. Gassler
N. Gassler
OLO. Linderkamp
O. Linderkamp
Fragestellung: Die primäre und sekundäre Surfactantdefizienz hat wesentlichen Anteil an der Morbidität und Letalität unreifer Frühgeborener. Insbesondere inflammatorische Prozesse tragen durch die Modulation von Surfactantfunktionen zu einer Verschlechterung der pulmonalen Situation bei. Das Glykoprotein DMBT1 (Deleted in Malignant Brain Tumors1) gehört zu der Gruppe B der scavenger receptor cysteine-rich Familie. Es spielt eine Rolle bei der Immunabwehr an mukosalen Oberflächen, indem es zahlreiche Bakterien und Viren bindet und agglutiniert. Ebenso interagiert es mit den Surfactantproteinen A und D, trägt zur Aktivierung der Chemokinese alveolärer Makrophagen bei und vermittelt die Aktivierung des Komplementsystems. Wir konnten mittels enzyme-linked immunosorbent assay (ELISA) nachweisen, dass bei einer Infektion im Trachealsekret frühgeborener Kinder hochsignifikant erhöhte DMBT1-Level vorliegen. Wir untersuchten die DMBT1-Expression im Lungengewebe verstorbener Früh- und Reifgeborener und bestimmten den Einfluss von DMBT1 auf die Funktion von Surfactant. Methodik: Mittels Immunhistochemie wurde die DMBT1-Expression in Lungenschnitten von 17 verstorbenen Früh- und Reifgeborenen unter Verwendung der Antikörper anti-DMBT1h12 (monoklonal) und anti-DMBT1p84 (polyklonal), die gegen verschiedene Regionen des Proteins gerichtet sind, untersucht. Den Einfluss von humanem rekombinanten DMBT1 (hrDMBT1) auf Rinder- und Schweinesurfactant (Alveofact, Curosurf) analysierten wir mithilfe eines capillary surfactometers (Calmia Medical, Toronto, ON, Canada). Ergebnisse: Die immunhistochemischen Analysen zeigten eine erhöhte DMBT1-Expression der Alveolen, Bronchiolen und Bronchien bei den Frühgeborenen mit Infektion im Vergleich zu denen ohne Infektion. hrDMBT1 erhöhte in vitro die Oberflächenspannung von Alveofact und Curosurf. Zugabe von Calcium inhibierte diesen Effekt. Dabei wurde – im Vergleich zu Curosurf – die Funktion von Alveofact durch geringere DMBT1-Mengen (100µg/ml vs. 200µg/ml) beeinflusst, und es war eine höhere Calcium-Menge (5mM CaCl2 vs. 1mM CaCl2) erforderlich, um die Surfactant-Funktion wiederherzustellen. Schlussfolgerung: Unsere Daten weisen darauf hin, dass die erhöhte Expression von DMBT1 in der Lunge bei Frühgeborenen mit Infektion zu einer nachteiligen Modulation der Funktion von bereits vorhandenem endogenen oder appliziertem exogenen Surfactant beitragen könnte.

15 July 2016 in Cancer Research
Verified
Journal Article
Closed access
PCPriya Chudasama
Priya Chudasama
MRMarcus Renner
Marcus Renner
KSKatja Specht
Katja Specht
SMSadaf Mughal
Sadaf Mughal
BHBarbara Hutter
Barbara Hutter
SFStefan Fröhling
Stefan Fröhling
Purpose: Soft-tissue sarcomas (STS) are highly diverse, devastating and clinically challenging malignancies. In advanced-stage STS, conventional chemotherapy provides symptom palliation but not prolonged survival, which typically ranges from 11-15 months after development of distant metastases. Thus, there is an urgent need for more effective, well-tolerated and targeted STS therapies. Alterations of the FGFR1 receptor tyrosine kinase are under investigation as biomarker of FGFR inhibitor sensitivity in several epithelial cancers. Prompted by the detection of high-level FGFR1 amplification in a patient with metastatic leiomyosarcoma through clinical exome sequencing, we investigated the role of FGFR1 as oncogenic driver and potential drug target in STS. Specific aims were to (i) determine the frequency of FGFR1 amplification and overexpression in adult STS, (ii) evaluate the sensitivity of FGFR1-altered STS cells to genetic and pharmacologic FGFR1 inhibition, and (iii) delineate the signaling pathways engaged by FGFR1 in these cells. Experimental design: The frequency of FGFR1 amplification and overexpression was established in a cohort of patients with treatment-näive high-grade STS using array-based comparative genomic hybridization and mRNA expression profiling, respectively, and results were validated using data from The Cancer Genome Atlas (TCGA). FGFR1 dependence was assessed in STS cell lines with and without FGFR1 alteration through RNA interference (RNAi)-mediated knockdown and selective small-molecule FGFR inhibitors. FGFR ligand and pharmacologic inhibitors were employed to dissect FGFR signaling in FGFR1-altered STS cells. Results: FGFR1 amplification and overexpression were present in 31% and 34% of cases in the untreated high-grade STS cohort (n = 176) and in 16% and 15% of cases in the TCGA cohort (n = 256). Interestingly, FGFR1 overexpression was detected in a substantial proportion of cases with no amplification (high-grade sarcoma cohort, 26%; TCGA cohort, 6.6%) comprising seven STS subtypes. Functional studies employing RNAi and different FGFR inhibitors (PD173074, AZD4547, BGJ398) demonstrated that the degree of dependence on FGFR1 for proliferation, survival, and anchorage-independent growth was primarily determined by FGFR1 expression levels. Furthermore, we identified the MAPK-ERK1/2 signaling axis as critical FGFR1 effector pathway whose suppression dictates the sensitivity of FGFR1-driven STS cells to FGFR-targeted therapy. Conclusions: FGFR1 amplification and overexpression are frequent events in multiple STS subtypes, and high FGFR1-expressing STS cells are sensitive to FGFR inhibition. These findings support FGFR1 as novel therapeutic target in STS and point to FGFR1 overexpression as a more reliable biomarker of sensitivity to FGFR pathway inhibition than genomic amplification, which might be of value for enrichment of future clinical trial populations. Citation Format: Priya Chudasama, Marcus Renner, Katja Specht, Sadaf Mughal, Barbara Hutter, Ingo Alldinger, Simon Schimmack, Dirk Jäger, Christof von Kalle, Stefan Gröschel, Stephan Wolf, Benedikt Brors, Wilko Weichert, Hanno Glimm, Gunhild Mechtersheimer, Claudia Scholl, Stefan Fröhling. FGFR1 overexpression is frequent in adult soft tissue sarcoma and predicts sensitivity to FGFR inhibitors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 457.